Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Pfizer on track to post best monthly gain in nearly three decades

Despite a threat to vaccine-driven immunity with the recent emergence of the new COVID-19 variant Omicron, $Pfizer (PFE.US)$ is on course to record its best monthly gain since Dec. 1991.
Over the past 12 months, the shares of the New York-based pharma giant has climbed ~40.8% well outperforming the broader index, as indicated in the graph below. Driven by the sales of the vaccine it co-developed with $BioNTech (BNTX.US)$ , its revenue has more than doubled over the past year.
Pfizer’s performance contrasts with rival vaccine maker $Moderna (MRNA.US)$ whose CEO has warned that the COVID-19 vaccines could lose efficacy against Omicron, classified by the World Health Organization (WHO) as a global variant of concern.
However, Pfizer targets both preventative and therapeutic aspects of the disease with its vaccine and the experimental COVID-19 pill Paxlovid, for which the company has already sought U.S. regulatory authorization.
Pfizer on track to post best monthly gain in nearly three decades
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
2
29
+0
13
Translate
Report
70K Views
Comment
Sign in to post a comment

View more comments...